EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Management of immune‐mediated necrotizing myopathy

Joome Suh, Anthony A Amato

Muscle & Nerve · 2024

DOI: 10.1002/mus.28114 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Muscle & Nerve, 2024. Verfasst von Joome Suh und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Myositis. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The immune‐mediated necrotizing myopathies (IMNM) are autoimmune myositides clinically characterized by proximal predominant weakness and elevated creatine kinase (CK). They may be associated with autoantibodies (anti‐HMGCR, anti‐SRP), triggered by statin use (e.g., anti‐HMGCR myopathy), associated with cancer, or may be idiopathic. Immunotherapy is required to improve strength and decrease the CK level, but no therapies are currently approved by the U.S. Food and Drug Administration for the treatment of IMNM. The optimal treatment strategy for IMNM is currently unknown and wide practice variation exists in the management of this condition. However, observational studies and expert opinion suggest that certain therapies may be more effective for the different serological subtypes of IMNM. HMGCR IMNM often responds favorably to intravenous immunoglobulin (IVIG) even as monotherapy. Signal recognition peptide and seronegative IMNM typically require combination immunotherapy, most often consisting of an oral immunosuppressant, corticosteroids, and IVIG or rituximab. Patients often remain on immunotherapy for years and relapse is common during tapering of immunotherapy. Further studies are needed to guide the optimal management of these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyositisHumansAutoimmune DiseasesImmunotherapyAutoantibodiesImmunoglobulins, IntravenousMuscular DiseasesHydroxymethylglutaryl CoA ReductasesNecrosisDisease Management

Stichwörter der Autor:innen

HMGCR myopathySRP myopathyimmune‐mediated necrotizing myopathynecrotizing autoimmune myopathystatin myopathy

Substanzen

AutoantibodiesImmunoglobulins, IntravenousHydroxymethylglutaryl CoA Reductases

Autor:innen und Institutionen

  • Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Zitieren

APA

Suh, J., & Amato, A. A. (2024). Management of immune‐mediated necrotizing myopathy. Muscle & Nerve. https://doi.org/10.1002/mus.28114

Vancouver

Suh J, Amato AA. Management of immune‐mediated necrotizing myopathy. Muscle & Nerve. 2024. doi:10.1002/mus.28114

BibTeX
@article{Suh2024,
  author = {Suh, Joome and Amato, Anthony A},
  title = {Management of immune‐mediated necrotizing myopathy},
  journal = {Muscle & Nerve},
  year = {2024},
  doi = {10.1002/mus.28114}
}
Kostenlos starten →